JPWO2022241430A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022241430A5 JPWO2022241430A5 JP2023569779A JP2023569779A JPWO2022241430A5 JP WO2022241430 A5 JPWO2022241430 A5 JP WO2022241430A5 JP 2023569779 A JP2023569779 A JP 2023569779A JP 2023569779 A JP2023569779 A JP 2023569779A JP WO2022241430 A5 JPWO2022241430 A5 JP WO2022241430A5
- Authority
- JP
- Japan
- Prior art keywords
- sbcma
- subject
- level
- therapy
- blood sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002560 therapeutic procedure Methods 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 39
- 210000004369 blood Anatomy 0.000 claims description 28
- 239000008280 blood Substances 0.000 claims description 28
- 208000034578 Multiple myelomas Diseases 0.000 claims description 18
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 18
- 229940020037 talquetamab Drugs 0.000 claims description 17
- 229940121623 teclistamab Drugs 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 208000007452 Plasmacytoma Diseases 0.000 claims description 10
- 206010061818 Disease progression Diseases 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 4
- 230000005750 disease progression Effects 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 2
- 238000002659 cell therapy Methods 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 238000000670 ligand binding assay Methods 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 238000002626 targeted therapy Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163187344P | 2021-05-11 | 2021-05-11 | |
| US63/187,344 | 2021-05-11 | ||
| PCT/US2022/072247 WO2022241430A1 (en) | 2021-05-11 | 2022-05-11 | Methods and compositions for monitoring the treatment of relapsed and/or refractory multiple myeloma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024520898A JP2024520898A (ja) | 2024-05-27 |
| JP2024520898A5 JP2024520898A5 (https=) | 2025-05-19 |
| JPWO2022241430A5 true JPWO2022241430A5 (https=) | 2025-05-19 |
Family
ID=82399377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023569779A Pending JP2024520898A (ja) | 2021-05-11 | 2022-05-11 | 再発性及び／又は難治性多発性骨髄腫の治療をモニタリングするための方法及び組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20220373550A1 (https=) |
| EP (1) | EP4337962A1 (https=) |
| JP (1) | JP2024520898A (https=) |
| KR (1) | KR20240005919A (https=) |
| CN (1) | CN117295949A (https=) |
| AU (1) | AU2022273326A1 (https=) |
| CA (1) | CA3219969A1 (https=) |
| MX (1) | MX2023013412A (https=) |
| TW (1) | TW202309522A (https=) |
| WO (1) | WO2022241430A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| CN116249548A (zh) | 2020-05-11 | 2023-06-09 | 詹森生物科技公司 | 用于治疗多发性骨髓瘤的方法 |
| IL312503A (en) | 2021-11-03 | 2024-07-01 | Janssen Biotech Inc | Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies |
| WO2024168192A1 (en) * | 2023-02-10 | 2024-08-15 | Celgene Corporation | Assessment of bcma in biological samples |
| CN121358492A (zh) * | 2023-04-19 | 2026-01-16 | 詹森生物科技公司 | 用于治疗多发性骨髓瘤的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
| US20030012783A1 (en) | 2001-02-20 | 2003-01-16 | Wayne Kindsvogel | Antibodies that bind both BCMA and TACI |
| JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
| EP2406284B9 (en) | 2009-03-10 | 2017-03-01 | Biogen MA Inc. | Anti-bcma antibodies |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| US10072088B2 (en) | 2015-08-17 | 2018-09-11 | Janssen Pharmaceutica, Nv | Anti-BCMA antibodies and uses thereof |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| EP4282877A3 (en) | 2016-08-10 | 2024-02-21 | Legend Biotech Ireland Limited | Chimeric antigen receptors targeting bcma and methods of use thereof |
| CN112955748A (zh) * | 2018-10-31 | 2021-06-11 | 葛兰素史密斯克莱知识产权发展有限公司 | 治疗癌症的方法 |
| AU2020377930A1 (en) * | 2019-11-05 | 2022-05-19 | Bristol-Myers Squibb Company | Uses of anti-BCMA chimeric antigen receptors |
-
2022
- 2022-05-10 TW TW111117430A patent/TW202309522A/zh unknown
- 2022-05-11 WO PCT/US2022/072247 patent/WO2022241430A1/en not_active Ceased
- 2022-05-11 KR KR1020237042423A patent/KR20240005919A/ko active Pending
- 2022-05-11 CN CN202280034423.8A patent/CN117295949A/zh active Pending
- 2022-05-11 US US17/742,076 patent/US20220373550A1/en not_active Abandoned
- 2022-05-11 EP EP22737692.8A patent/EP4337962A1/en active Pending
- 2022-05-11 CA CA3219969A patent/CA3219969A1/en active Pending
- 2022-05-11 AU AU2022273326A patent/AU2022273326A1/en not_active Abandoned
- 2022-05-11 JP JP2023569779A patent/JP2024520898A/ja active Pending
- 2022-05-11 MX MX2023013412A patent/MX2023013412A/es unknown
-
2025
- 2025-07-25 US US19/281,154 patent/US20250362298A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hu et al. | Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2‐positive gastric cancer | |
| de Mingo Pulido et al. | TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer | |
| Munari et al. | Cytokine BAFF released by Helicobacter pylori–infected macrophages triggers the Th17 response in human chronic gastritis | |
| US12485174B2 (en) | HDAC6-activated macrophages, compositions, and uses thereof | |
| Marks et al. | Innate immunity in inflammatory bowel disease: a disease hypothesis | |
| US10703820B2 (en) | Methods and compositions for reducing cardiac damage and other conditions | |
| Qu et al. | ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma | |
| US20230256053A1 (en) | Methods and compositions for immunomodulation | |
| JP2013127469A (ja) | ＩＬ−１α自己抗体を用いた血管障害の診断、処置、および予防 | |
| Meng et al. | Valsartan attenuates atherosclerosis via upregulating the Th2 immune response in prolonged angiotensin II-treated ApoE−/− mice | |
| JP6789117B2 (ja) | 免疫媒介性疾患を有する対象を処置するための組成物および方法 | |
| Kobold et al. | The macrophage migration inhibitory factor (MIF)-homologue D-dopachrome tautomerase is a therapeutic target in a murine melanoma model | |
| Liao et al. | Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review | |
| Blaschke et al. | Haptoglobin-α1,-α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis | |
| IL275438B1 (en) | Biomarkers of methotrexate-induced immune tolerance | |
| Xie et al. | Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma | |
| Zhang et al. | Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L) 1 therapy: a systematic review | |
| Liang et al. | PITPNC1 suppress CD8+ T cell immune function and promote radioresistance in rectal cancer by modulating FASN/CD155 | |
| Wang et al. | Blocking HMGB1 signal pathway protects early radiation-induced lung injury | |
| Wöhrl et al. | Pemphigoid gestationis: treatment with immunoapheresis: pemphigoid gestationis: Behandlung durch Immunapherese | |
| Nishiura et al. | Interleukin‐21 and tumor necrosis factor‐α are critical for the development of autoimmune gastritis in mice | |
| EP0325847A1 (en) | Method for the selection of anti-idiotype antibodies, and their use in the diagnosis, monitoring and treatment of disease | |
| JPWO2022241430A5 (https=) | ||
| Wood et al. | Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis | |
| Teunissen et al. | MAb therapy against the IFN-α/β receptor subunit 1 stimulates arteriogenesis in a murine hindlimb ischaemia model without enhancing atherosclerotic burden |